PDF
ePub
Citation
Print
Abstract
The management of prostate cancer which is common in the elderly is problematic and remains controversial. Patient selection may have a crucial role in predicting outcome, because of death from other causes may occur before death from prostate cancer in many cases. The best approach may be to have patients choose a therapy after being well informed of the outcome including the relative risks and benefits from each treatment option. Assessment of treatment outcome has become more sensitive and rapid after serum prostate specific antigen (PSA) is available in routine follow-up. PSA has identified substantially more failure following all radical therapies than was previously detected, which is reporting long-term outcome with cure rates well below 40% not only for surgery but also radiation. Though watchful waiting or conservative management is frequently criticized as a poor option, it maybe a valid option for all men regardless of age or health status. However, radical prostatectomy still offers the best opportunity to cure the disease Because of uncertainty of therapeutic benefit and variation in practice patterns etc, practice guideline development is needed.
References
1. Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol. 1994. 152(5 Pt 2):1766–1768.
2. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J Urol. 1994. 152(5 Pt 2):1806–1812.
3. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994. 152(5 Pt 2):1850–1857.
4. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol. 1998. 160(4):1392–1397.
5. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol. 1999. 162(6):2024–2028.
6. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 1995. 154(2 Pt 1):424–428.
7. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol. 1994. 152(5 Pt 2):1781–1785.
8. Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D. Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials. J Urol. 1999. 161(3):864–868.
9. Powell CR, Huisman TK, Riffenburgh RH, Saunders EL, Bethel KJ, Johnstone PA. Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol. 1997. 157(5):1754–1759.
10. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol. 1999. 162(2):421–426.
11. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004. 171(3):1137–1140.
12. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998. 159(6):2030–2034.
13. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Pierart M, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997. 337(5):295–300.
14. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Stoeckle M, et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol. 2004. 171(3):1128–1131.
15. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. Cancer. 1998. 83(5):989–1001.
16. Johansson JE. Expectant management of early stage prostatic cancer:Swedish experience. J Urol. 1994. 152(5 Pt 2):1753–1756.
17. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Kolvenbag GJ, et al. Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002. 168(2):429–435.
18. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Warner J, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994. 330(4):242–248.
19. Hanks GE, Hanlon A, Schultheiss T, Corn B, Shipley WU, Lee WR. Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J Urol. 1994. 152(5 Pt 2):1775–1780.
20. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995. 154(2 Pt 1):460–465.
21. Lundgren R, Nordle O, Josefsson K. The South Sweden Prostate Cancer Study Group. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. J Urol. 1995. 153(5):1580–1586.
22. Glass TR, Tangen CM, Crawford ED, Thompson I. Meta-static carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003. 169(1):164–169.
23. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002. 168(6):2439–2443.
24. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Rosenkilde P, et al. Danish Prostatic Cancer Group. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol. 1997. 157(3):929–934.
25. Penedo FJ, Dahn JR, Molton I, Gonzalez JS, Kinsinger D, Antoni MH, et al. Cognitive-behavioral stress management improves stress-management skills and quality of life in men recovering from treatment of prostate carcinoma. Cancer. 2004. 100(1):192–200.
26. Chodak GW. The role of conservative management in localized prostate cancer. Cancer. 1994. 74:Suppl 7. 2178–2181.
27. Austenfeld MS, Thompson IM Jr, Middleton RG. Metaanalysis of the literature: guideline development for prostate cancer treatment. American Urological Association Prostate Cancer Guideline Panel. J Urol. 1994. 152(5 Pt 2):1866–1869.
28. Bonney WW, Schned AR, Timberlake DS. Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials. J Urol. 1998. 160(5):1754–1760.
XML Download